EBS Stock Overview
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Emergent BioSolutions Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.47 |
52 Week High | US$13.67 |
52 Week Low | US$1.42 |
Beta | 1.22 |
1 Month Change | 58.33% |
3 Month Change | 1.23% |
1 Year Change | -69.39% |
3 Year Change | -97.40% |
5 Year Change | -94.96% |
Change since IPO | -78.89% |
Recent News & Updates
Recent updates
New CEO Appointment A Clear Positive For Emergent BioSolutions
Feb 27Emergent BioSolutions: Q3 Numbers Leave Work To Be Done
Dec 18Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow
Nov 23Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
Aug 23Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)
Aug 14Emergent BioSolutions: Making A Big Bet On Narcan
Jul 21An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued
Jun 22Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?
Apr 05Emergent Biosolutions Q4 2022 Earnings Preview
Feb 24An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued
Feb 16Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M
Feb 15Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments
Dec 07Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance
Nov 09Emergent doses first participant in Phase 1 trial for Lassa virus vaccine
Sep 06Emergent BioSolutions: Now Long Through Sale Of October Put Spreads
Aug 24A Look At The Fair Value Of Emergent BioSolutions Inc. (NYSE:EBS)
Aug 13Additional 135M COVID-19 vaccine doses destroyed at Emergent BioSolutions Baltimore plant
Aug 12Emergent BioSolutions misses on top and bottom lines as it swings to quarterly loss
Aug 01Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic
Jul 26Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
Jul 26Kamada inks $11.4 M supply deal for chickenpox preventive antibody Varizig
Jul 06Emergent BioSolutions: A Top Pick For The Monkeypox Outbreak
May 29Emergent BioSolutions Inc. (NYSE:EBS) Shares Could Be 37% Below Their Intrinsic Value Estimate
May 12Emergent BioSolutions (NYSE:EBS) Has A Pretty Healthy Balance Sheet
Apr 24Shareholder Returns
EBS | US Biotechs | US Market | |
---|---|---|---|
7D | -11.8% | -2.1% | -0.1% |
1Y | -69.4% | 10.4% | 28.4% |
Return vs Industry: EBS underperformed the US Biotechs industry which returned 10.4% over the past year.
Return vs Market: EBS underperformed the US Market which returned 28.4% over the past year.
Price Volatility
EBS volatility | |
---|---|
EBS Average Weekly Movement | 26.7% |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EBS's share price has been volatile over the past 3 months.
Volatility Over Time: EBS's weekly volatility has increased from 17% to 27% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 1,600 | Joe Papa | https://www.emergentbiosolutions.com |
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector.
Emergent BioSolutions Inc. Fundamentals Summary
EBS fundamental statistics | |
---|---|
Market cap | US$127.90m |
Earnings (TTM) | -US$760.50m |
Revenue (TTM) | US$1.05b |
0.1x
P/S Ratio-0.2x
P/E RatioIs EBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EBS income statement (TTM) | |
---|---|
Revenue | US$1.05b |
Cost of Revenue | US$807.10m |
Gross Profit | US$242.20m |
Other Expenses | US$1.00b |
Earnings | -US$760.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -14.57 |
Gross Margin | 23.08% |
Net Profit Margin | -72.48% |
Debt/Equity Ratio | 132.5% |
How did EBS perform over the long term?
See historical performance and comparison